Highlights Better Therapeutics, Inc.

Equities

BTTX

US08773T1043

Market Closed - OTC Markets Other stock markets 14:52:54 2024-05-13 EDT			5-day change	1st Jan Change
0.0122 ^USD	+11.74%		+4.27%	-93.74%

03-21	Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc	CI
03-20	Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from S&P TMI Index	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Better Therapeutics Gets Breakthrough Device Designation For Cognitive Behavioral Therapy Platform	02-20	DJ
Better Therapeutics, Inc. Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease	02-20	CI
Better Therapeutics Inc. Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx Is More Effective and Less Costly Than Standard of Care Alone	01-17	CI
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States	01-03	CI
Better Therapeutics Seeks FDA Breakthrough Device Designation for Prescription Digital Therapeutics Targeting Liver Diseases	01-02	MT
Better Therapeutics, Inc. Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease	01-02	CI
Better Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Better Therapeutics, Inc. Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes	23-10-11	CI
Better Therapeutics, Inc. Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes	23-09-28	CI
Better Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Better Therapeutics, Inc. Receives Fda Authorization for Aspyrerx to Treat Adults with Type 2 Diabetes	23-07-10	CI
Better Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Better Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Better Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-30	CI
Better Therapeutics, Inc. Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results	22-12-08	CI
Better Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Better Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates	22-11-14	BU
Better Therapeutics, Inc Announces Positive Results from Pivotal Trial of Better Therapeutics' Investigational BT-001 Prescription Digital Therapy for Type 2 Diabetes Published in Diabetes Care	22-10-04	CI
Better Therapeutics, Inc. Submits De Novo Request to U.S. FDA for BT-001 Investigational Prescription Digital Therapy for Type 2 Diabetes	22-09-22	CI
Better Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Better Therapeutics, Inc.

Equities

BTTX

US08773T1043

Highlights

Filters